Imperial and Apollo developing potential treatment for pulmonary hypertension
A partnership designed to rapidly turn scientific breakthroughs into medicines has yielded a potential treatment for pulmonary arterial hypertension.
Six things we learnt about environmental innovation at All You Can Innovate
Researchers and entrepreneurs shared hard-won lessons on bringing environmental solutions to market at an All You Can Innovate event last month.
Imperial spinout Siftr Bio aims to improve precision of ADC cancer drugs
A new Imperial spinout aims to improve the performance of an emerging class of cancer treatments known as antibody-drug conjugates or ADCs.
It’s unusual that you shared negative data, spinout told, pre £90m raise
Honesty is the best policy, says Myricx's CEO, who used authentic relationships with investors to help the biotech win major funding after a pivot.
NHS using Imperial spinout’s advanced prescription software to improve safety
Imperial spinout Dosium is working with the NHS to roll out a clinical decision support tool that provides dosage guidance to increase patient safety.
2
New tool could transform study of cells and help find new drug targets
A new tool from Imperial and Molecular Dimensions could help biologists rapidly uncover valuable insights into the proteins found in cell membranes.
Imperial team awarded £5m from BHF to support world-leading heart research
The British Heart Foundation has awarded funding to advance cardiovascular research and ‘digital twins’ technology.
Feature
Eight things we learned about commercialising medical research at AYCI 2024
We learnt why you should channel Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.
Imperial President - College making big moves to accelerate medical innovation
Professor Hugh Brady says that Imperial is working to speed development of innovations that have potential to be as transformational as penicillin.
Apollo Therapeutics raises $226.5m to develop medicines based on uni research
Company founded by the tech transfer offices of Imperial, Cambridge and UCL has raised major Series C funding to turn basic research into medicines.
